AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-TESTING LABORATORIES
20/20 Biolabs, Inc. Common Stock
XNAS · usd
SIC 8734 · SERVICES-TESTING LABORATORIES
FIGI BBG01ZZ5RTV4
0.24▼ 0.02 (-6.18%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
0.25
Day's Range
0.24 – 0.27
52-Week Range
0.24 – 50.00
Volume
191.5K
Avg Volume
102.7K
Share Statistics
Shares Outstanding
Employees
14
Exchange
XNAS
Listed
2026-02-19
Share count as of August 14, 2026

20/20 Biolabs, Inc. Common Stock (AIDX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about 20/20 Biolabs, Inc. Common Stock (AIDX)
What is 20/20 Biolabs, Inc. Common Stock's Market Cap?
20/20 Biolabs, Inc. Common Stock's Market Cap is $3.0M, based on as-reported figures from SEC (XBRL) filings.
What is 20/20 Biolabs, Inc. Common Stock's Enterprise Value?
20/20 Biolabs, Inc. Common Stock's Enterprise Value is -$1.2M, based on as-reported figures from SEC (XBRL) filings.
What is 20/20 Biolabs, Inc. Common Stock's Price / Sales?
20/20 Biolabs, Inc. Common Stock's Price / Sales is 1.6×, based on as-reported figures from SEC (XBRL) filings.
What is 20/20 Biolabs, Inc. Common Stock's EV / Revenue?
20/20 Biolabs, Inc. Common Stock's EV / Revenue is n/m, based on as-reported figures from SEC (XBRL) filings.
What is 20/20 Biolabs, Inc. Common Stock's EV / EBITDA?
20/20 Biolabs, Inc. Common Stock's EV / EBITDA is 0.3×, based on as-reported figures from SEC (XBRL) filings.
What is 20/20 Biolabs, Inc. Common Stock's Revenue (TTM)?
20/20 Biolabs, Inc. Common Stock's Revenue (TTM) is $1.8M, based on as-reported figures from SEC (XBRL) filings.
What is 20/20 Biolabs, Inc. Common Stock's Net Income (TTM)?
20/20 Biolabs, Inc. Common Stock's Net Income (TTM) is -$5.1M, based on as-reported figures from SEC (XBRL) filings.
What is 20/20 Biolabs, Inc. Common Stock's EBITDA?
20/20 Biolabs, Inc. Common Stock's EBITDA is -$3.9M, based on as-reported figures from SEC (XBRL) filings.
What is 20/20 Biolabs, Inc. Common Stock's Diluted EPS (TTM)?
20/20 Biolabs, Inc. Common Stock's Diluted EPS (TTM) is -0.40, based on as-reported figures from SEC (XBRL) filings.
What is 20/20 Biolabs, Inc. Common Stock's EBITDA Margin?
20/20 Biolabs, Inc. Common Stock's EBITDA Margin is -213.8%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · AIDXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Jun 30, 2025Mar 31, 2025
Revenues
Cost of revenues
Gross profit
% of revenue41.7%17.8%
Operating expenses:
Sales, general and administrative
Research and development
Total operating expenses
% of revenue212.0%426.2%
Operating loss
% of revenue-170.3%-408.4%
Other (expense) income:
Interest expense
Interest income
Loss on change in fair value of warrant liability
Loss on issuance of convertible note
Other expense, net—
Total other (expense) income
Net loss
% of revenue-206.2%-615.4%
Preferred stock dividends
Net loss attributable to common stockholders
Basic net loss per common share (in Dollars per share)
Diluted net loss per common share (in Dollars per share)